✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
CTA018 is an investigational drug.
There have been 3 clinical trials for CTA018. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2006.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Neoplasm Metastasis, and Kidney Failure, Chronic. The leading clinical trial sponsors are OPKO Health, Inc., OPKO IP Holdings II, Inc., and [disabled in preview].
Recent Clinical Trials for CTA018
|Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)||OPKO Health, Inc.||Phase 2|
|Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease||OPKO IP Holdings II, Inc.||Phase 2|
|Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis||OPKO Health, Inc.||Phase 2|